Multinational Evidence-based Recommendations for the Use of Methotrexate in Rheumatic Disorders with a Focus on Rheumatoid Arthritis: Integrating Systematic Literature Research and Expert Opinion of a Broad International Panel of Rheumatologists In...

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2008 Nov 27

PMID 19033291

Citations 134

Authors

K Visser

W Katchamart

E Loza

J A Martinez-Lopez

C Salliot

J Trudeau

C Bombardier

L Carmona

D van der Heijde

J W J Bijlsma

D T Boumpas

H Canhao

C J Edwards

V Hamuryudan

T K Kvien

B F Leeb

E M Martin-Mola

H Mielants

U Muller-Ladner

G Murphy

M Ostergaard

I A Pereira

C Ramos-Remus

G Valentini

J Zochling

M Dougados

Affiliations

Soon will be listed here.

Abstract

Objectives: To develop evidence-based recommendations for the use of methotrexate in daily clinical practice in rheumatic disorders.

Methods: 751 rheumatologists from 17 countries participated in the 3E (Evidence, Expertise, Exchange) Initiative of 2007-8 consisting of three separate rounds of discussions and Delphi votes. Ten clinical questions concerning the use of methotrexate in rheumatic disorders were formulated. A systematic literature search in Medline, Embase, Cochrane Library and 2005-7 American College of Rheumatology/European League Against Rheumatism meeting abstracts was conducted. Selected articles were systematically reviewed and the evidence was appraised according to the Oxford levels of evidence. Each country elaborated a set of national recommendations. Finally, multinational recommendations were formulated and agreement among the participants and the potential impact on their clinical practice was assessed.

Results: A total of 16 979 references was identified, of which 304 articles were included in the systematic reviews. Ten multinational key recommendations on the use of methotrexate were formulated. Nine recommendations were specific for rheumatoid arthritis (RA), including the work-up before initiating methotrexate, optimal dosage and route, use of folic acid, monitoring, management of hepatotoxicity, long-term safety, mono versus combination therapy and management in the perioperative period and before/during pregnancy. One recommendation concerned methotrexate as a steroid-sparing agent in other rheumatic diseases.

Conclusions: Ten recommendations for the use of methotrexate in daily clinical practice focussed on RA were developed, which are evidence based and supported by a large panel of rheumatologists, enhancing their validity and practical use.

Citing Articles

Biological, dietetic and pharmacological properties of vitamin B.

Siatka T, Matus M, Moravcova M, Harcarova P, Lomozova Z, Matousova K NPJ Sci Food. 2025; 9(1):30.

PMID: 40075081 PMC: 11904035. DOI: 10.1038/s41538-025-00396-w.

Utility of the GerdQ questionnaire in detecting gastroesophageal symptoms with RA patients.

Nozaki Y, Kishimoto K, Tomita D, Itami T, Ashida C, Kinoshita K BMC Rheumatol. 2024; 8(1):73.

PMID: 39716318 PMC: 11664924. DOI: 10.1186/s41927-024-00442-2.

Predictors of methotrexate adherence and patient's awareness of it in rheumatoid arthritis and its effect on quality of life.

Mohamed M, El-Maboud A, Salem H, Salem M, Elmaaty M, Eissa N J Pharm Policy Pract. 2024; 17(1):2365933.

PMID: 39035456 PMC: 11259066. DOI: 10.1080/20523211.2024.2365933.

Deciphering the therapeutic potential of trimetazidine in rheumatoid arthritis targeting mi-RNA128a, TLR4 signaling pathway, and adenosine-induced FADD-microvesicular shedding: and study.

Omran E, Alzahrani A, Ezzat S, Ellithy G, Tarek M, Khairy E Front Pharmacol. 2024; 15:1406939.

PMID: 38919260 PMC: 11196411. DOI: 10.3389/fphar.2024.1406939.

Unveiling Novel Drug Targets and Emerging Therapies for Rheumatoid Arthritis: A Comprehensive Review.

Khokhar M, Dey S, Tomo S, Jaremko M, Emwas A, Pandey R ACS Pharmacol Transl Sci. 2024; 7(6):1664-1693.

PMID: 38898941 PMC: 11184612. DOI: 10.1021/acsptsci.4c00067.

References

Criswell L, Henke C . What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis?. J Rheumatol. 1995; 22(5):829-35. View

Ujfalussy I, Koo E, Sesztak M, Gergely P . Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases. Z Rheumatol. 2003; 62(2):155-60. DOI: 10.1007/s00393-003-0458-2. View

Katchamart W, Trudeau J, Phumethum V, Bombardier C . Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2008; 68(7):1105-12. PMC: 2689526. DOI: 10.1136/ard.2008.099861. View

Kamel O, Weiss L, van de Rijn M, Colby T, Kingma D, Jaffe E . Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol. 1996; 20(10):1279-87. DOI: 10.1097/00000478-199610000-00015. View

Shergy W, Polisson R, Caldwell D, Rice J, Pisetsky D, Allen N . Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med. 1988; 85(6):771-4. DOI: 10.1016/s0002-9343(88)80019-6. View

Kozlowski R, Steinbrunner J, MacKenzie A, Clough J, Wilke W, Segal A . Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med. 1990; 88(6):589-92. DOI: 10.1016/0002-9343(90)90522-f. View

Alarcon G, Kremer J, Macaluso M, Weinblatt M, Cannon G, Palmer W . Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997; 127(5):356-64. DOI: 10.7326/0003-4819-127-5-199709010-00003. View

Kamel O, van de Rijn M, LeBrun D, Weiss L, Warnke R, DORFMAN R . Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol. 1994; 25(7):638-43. DOI: 10.1016/0046-8177(94)90295-x. View

Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J . Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002; 99(11):3909-15. DOI: 10.1182/blood.v99.11.3909. View

10.

Assous N, Touze E, Meune C, Kahan A, Allanore Y . Cardiovascular disease in rheumatoid arthritis: single-center hospital-based cohort study in France. Joint Bone Spine. 2006; 74(1):66-72. DOI: 10.1016/j.jbspin.2006.10.001. View

11.

Ros S, Juanola X, Condom E, Canas C, Riera J, Guardiola J . Light and electron microscopic analysis of liver biopsy samples from rheumatoid arthritis patients receiving long-term methotrexate therapy. Scand J Rheumatol. 2002; 31(6):330-6. DOI: 10.1080/030097402320817040. View

12.

Haagsma C, van Riel P, de Jong A, van de Putte L . Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol. 1997; 36(10):1082-8. DOI: 10.1093/rheumatology/36.10.1082. View

13.

Jundt J, Browne B, Fiocco G, Steele A, Mock D . A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993; 20(11):1845-9. View

14.

Buckley L, Vacek P, Cooper S . Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1990; 17(9):1158-61. View

15.

Kremer J, Furst D, Weinblatt M, Blotner S . Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol. 1996; 23(3):459-61. View

16.

Beyeler C, Jordi B, Gerber N, Im Hof V . Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol. 1996; 35(5):446-52. DOI: 10.1093/rheumatology/35.5.446. View

17.

Espinoza L, Zakraoui L, Espinoza C, Gutierrez F, Jara L, Silveira L . Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol. 1992; 19(6):872-7. View

18.

Alarcon G, Tracy I, Strand G, Singh K, Macaluso M . Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis. 1995; 54(9):708-12. PMC: 1009984. DOI: 10.1136/ard.54.9.708. View

19.

Chakravarty E, Sanchez-Yamamoto D, Bush T . The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol. 2003; 30(2):241-6. View

20.

Ferraccioli G, Salaffi F, De Vita S, Casatta L, Bartoli E . Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol. 1996; 23(4):624-8. View